ArticleNPJ breast cancer2022

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer.

Igor Makhlin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.